MTA3 and gastroesophageal junction adenocarcinoma: Future research should aim to elucidate the epigenetic mechanisms governing MTA3 expression in GEJ adenocarcinoma, validate its clinical utility as a prognostic biomarker, and develop targeted therapeutic strategies for the MTA3/Snail/E-cadherin signaling pathway.